Trial reportAging clinical and experimental research2026
Reducing concerns about falling in older adults: evaluation of a multi-component intervention and the role of stress and inflammation markers - long-term effects of the FEARFALL randomized controlled trial.
Trial report in Aging clinical and experimental research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConcerns about falling (CaF) are common in older adults and associated with reduced activity and poorer health. This study investigated, for the first time, the long-term effects of a multi-component intervention targeting CaF on psychological, functional, biophysiological, and anthropometric outcomes.
methods160 community-dwelling older adults (≥ 70 years) were randomly assigned to a 4-month intervention featuring exercise and cognitive-behavioral training or to a sham control group. CaF and related psychological outcomes were assessed using validated questionnaires. Salivary cortisol and α-amylase, physical function, activity, body composition and inflammatory markers (C-reactive protein [CRP]-, interleukin-6 [IL-6], interleukin-10 [IL-10], interleukin-1β [IL-1β] and tumor necrosis factor-alpha [TNF-α]) were analyzed at baseline, post-intervention, and 8-month follow-up.
resultsAll estimates represent T0-T2 estimated marginal mean differences. There was no intervention effect or long-term superiority between the groups. Significant time effects were observed for CaF and physiological biomarkers for stress axis activity and inflammatory markers. Functional outcomes changed only marginally.
conclusionCaF improved similarly in both groups. Changes in basal stress system activity and inflammatory cytokines were highly comparable between groups. Contrary to our hypothesis, the intervention did not confer additional benefits over the sham control intervention in reducing CaF.
trial registrationGerman Clinical Trials Register (DRKS): DRKS00029171. Registered 22 July 2022, https://drks.de/search/de/trial/DRKS00029171 .
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.